NICE’s Final Appraisal Determination On Torisel (R) (temsirolimus) Denies A Life Extending Treatment To Advanced Kidney Cancer Patients

The most seriously ill patients with advanced renal cell (kidney) cancer will be denied the life extending medicine Torisel (temsirolimus) if the recommendations in the Final Appraisal Determination (FAD) published by the National Institute for Health and Clinical Excellence (NICE) today are adopted.1 This FAD discriminates against a small group of patients with the poorest prognosis by failing to recommend a treatment indicated exclusivelyfor them.

More: continued here

Filed under: Urology on May 3rd, 2009